These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15622324)

  • 1. Soluble toll-like receptor 2 in HIV infection: association with disease progression.
    Heggelund L; Flo T; Berg K; Lien E; Mollnes TE; Ueland T; Aukrust P; Espevik T; Frøland SS
    AIDS; 2004 Dec; 18(18):2437-9. PubMed ID: 15622324
    [No Abstract]   [Full Text] [Related]  

  • 2. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection.
    Lester RT; Yao XD; Ball TB; McKinnon LR; Kaul R; Wachihi C; Jaoko W; Plummer FA; Rosenthal KL
    AIDS; 2008 Mar; 22(6):685-94. PubMed ID: 18356597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
    Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection.
    Lascar RM; Lopes AR; Gilson RJ; Dunn C; Johnstone R; Copas A; Reignat S; Webster G; Bertoletti A; Maini MK
    J Infect Dis; 2005 Apr; 191(7):1169-79. PubMed ID: 15747254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron status and mortality in HIV infection.
    Weinberg GA
    Haematologica; 2006 Jun; 91(6):721. PubMed ID: 16769564
    [No Abstract]   [Full Text] [Related]  

  • 7. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration.
    Jaroszewicz J; Wiercinska-Drapalo A; Lapinski TW; Prokopowicz D; Rogalska M; Parfieniuk A
    Antivir Ther; 2006; 11(5):641-5. PubMed ID: 16964834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced levels of the CCR7 ligands CCL19 and CCL21 in HIV infection: correlation with viral load, disease progression and response to highly active antiretroviral therapy.
    Damås JK; Landrø L; Fevang B; Heggelund L; Frøland SS; Aukrust P
    AIDS; 2009 Jan; 23(1):135-8. PubMed ID: 19050397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
    Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
    J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression.
    Casoli C; Pilotti E; Bertazzoni U
    AIDS Rev; 2007; 9(3):140-9. PubMed ID: 17982939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and function of Toll-like receptor 2 in canine blood phagocytes.
    Bazzocchi C; Mortarino M; Comazzi S; Bandi C; Franceschi A; Genchi C
    Vet Immunol Immunopathol; 2005 Mar; 104(1-2):15-9. PubMed ID: 15661327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
    Kvale D; Ormaasen V; Kran AM; Johansson CC; Aukrust P; Aandahl EM; Frøland SS; Taskén K
    AIDS; 2006 Apr; 20(6):813-20. PubMed ID: 16549964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human-immunodeficiency-virus-infected patients: findings of the Anemia Prevalence Study.
    Mildvan D; Creagh T; Leitz G;
    Curr Med Res Opin; 2007 Feb; 23(2):343-55. PubMed ID: 17288689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection.
    Kamga I; Kahi S; Develioglu L; Lichtner M; Marañón C; Deveau C; Meyer L; Goujard C; Lebon P; Sinet M; Hosmalin A
    J Infect Dis; 2005 Jul; 192(2):303-10. PubMed ID: 15962225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.